Close Menu

Clostridium difficile

The Quebec City, Canada-based firm will launch its point-of-care molecular platform with GBS and C. diff tests next year as CE-IVD products. 

The Austin, Texas-based molecular diagnostics firm logged $60.6 million in Q3 revenues as its system sales shot up 26 percent to $9.6 million.

The results confirm previous findings suggesting molecular tests may not be the best tool guide treatment for Clostridium difficile infection, and toxin assays are necessary.

Using Quanterix's Simoa technology, the group developed assays to detect C. diff toxins with a high degree of sensitivity and specificity.

The assay is the first on the firm's isothermal nucleic acid amplification-based platform.

The test adds to a growing menu of approved assays for the cobas 4800 system.

Researchers from the Public Health Agency of Sweden have developed an approach for typing Clostridium difficile isolates based on their patterns of high-molecular weight proteins.

Diagnostics revenues at the company jumped 5 percent organically driven in part by a 16 percent increase in sales of illumigene molecular diagnostic products.

The waiver opens up a significant new opportunity for Alere within the physician office market, according to a company executive.

Pages

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.